We also utilized different preclinical mouse models, including patient-derived xenograft (PDX) mouse models, to evaluate the effects of tasquinimod, a drug that inhibits S100A9 and can reduce the pro-tumor effects of S100A9. This evidence concerns the gene S100A9 and neoplasm.